Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope

The development of selective anticancer vaccines that provide enhanced protection against tumor recurrence and metastasis has been the subject of intense research in the scientific community. The tumor-associated glycoprotein MUC1 represents a well-established target for cancer immunotherapy and has been used for the construction of various synthetic vaccine candidates. However, many of these vaccine prototypes suffer from an inherent low immunogenicity and are susceptible to rapid in vivo degradation. To overcome these drawbacks, novel fluorinated MUC1 glycopeptide-BSA/TTox conjugate vaccines have been prepared. Immunization of mice with the 4' F-TF-MUC1-TTox conjugate resulted in strong immune responses overriding the natural tolerance against MUC1 and producing selective IgG antibodies that are cross-reactive with native MUC1 epitopes on MCF-7 human cancer cells

Photocontrolled Chignolin-Derived ß-Hairpin Peptidomimetics

Supramolecular templating techniques have been widely used to direct the formation of porous materials with the goal of introducing permanent mesoporosity. While surfactant-directed self-assembly has been exploited for inorganic materials such as titania, silica, organosilica, and zeolites, it has rarely been applied to metal-organic frameworks (MOFs) and coordination polymers. Here we introduce a new family of gemini surfactant-directed zinc imidazolates, referred to as mesostructured imidazolate frameworks (MIFs), and present a detailed study on the influence of different gemini-type surfactants on the formation mechanism and structures of the resulting zinc imidazolates. The proposed formation mechanism for MIF-type materials involves co-assembly and crystallization processes that yield lamellar mesostructured imidazolate frameworks. Understanding and controlling such processes also has implications for the syntheses of microporous zinc imidazolate framework (ZIF) materials, whose formation can be suppressed in surfactant-rich solutions, whereas formation of MIF materials is favored in the presence of surfactants and triggered by the addition of halogenides. Solid-state 2D 13C1H HETCOR NMR measurements on prototypic CTAB-directed MIF-1 establish that the head group moieties of the surfactant molecules interact strongly with the zinc-imidazolate-bromide sheets. Additionally, the NMR analyses suggest that MIF-1 has a significant fraction of surfactant molecules that are interdigitated between the zinc-imidazolate-bromide sheets with an antiparallel stacking arrangement, consistent with the high thermal and chemical stability of the MIF hybrid materials

Synthesis of tumor-associated MUC1-glycopeptides and their multivalent presentation by functionalized gold colloids

The mucin MUC1 is a glycoprotein involved in fundamental biological processes, which can be found over-expressed and with a distinctly altered glycan pattern on epithelial tumor cells; thus it is a promising target structure in the quest for effective carbohydrate-based cancer vaccines and immunotherapeutics. Natural glycopeptide antigens indicate only a low immunogenicity and a T-cell independent immune response; however, this major drawback can be overcome by coupling of glycopeptide antigens multivalently to immunostimulating carrier platforms. In particular, gold nanoparticles are well suited as templates for the multivalent presentation of glycopeptide antigens, due to their remarkably high surface-to-volume ratio in combination with their high biostability. In this work the synthesis of novel MUC1-glycopeptide antigens and their coupling to gold nanoparticles of different sizes are presented. In addition, the development of a new dot-blot immunoassay to test the potential antigen-antibody binding is introduced

(1R,4′S)-4-(tert-Butyl­dimethyl­silan­oxy)-1-[2,2-dimethyl-3-(p-tolyl­sulfon­yl)-1,3-oxazolidin-4-yl]but-2-yn-1-ol

The chiral title compound, C22H35NO5SSi, is a precursor of novel furan­omycin derivatives. It crystallizes with two molecules in the asymmetric unit; these show different conformations of the silyl substitutent, as indicated by the Si—O—C—C torsion angles of 41.4 (7) and −84.5 (5)° in the two mol­ecules. The anti configuration of the adjacent stereogenic centers is consistent with the Felkin–Anh model. Each of the two crystallographically independent mol­ecules is connected with a neighbouring mol­ecule of the same type via two symmetry-equivalent O—H⋯O hydrogen bonds

Optical control of a receptor-linked guanylyl cyclase using a photoswitchable peptidic hormone

The photoswitchable peptidomimetic hormone TOP271 allows the precise optical control of cGMP generation via the receptor-linked enzyme NPR-A in explanted aortic rings and islets of Langerhans.</p

Conditional and Reversible Activation of Class A and B G Protein-Coupled Receptors Using Tethered Pharmacology

Understanding the activation and internalization of G protein-coupled receptors (GPCRs) using conditional approaches is paramount to developing new therapeutic strategies. Here, we describe the design, synthesis, and testing of ExONatide, a benzylguanine-linked peptide agonist of the glucagon-like peptide-1 receptor (GLP-1R), a class B GPCR required for maintenance of glucose levels in humans. ExONatide covalently binds to SNAP-tagged GLP-1R-expressing cells, leading to prolonged cAMP generation, Ca2+ rises, and intracellular retention of the receptor. These effects were readily switched OFF following cleavage of the introduced disulfide bridge using the cell-permeable reducing agent beta-mercaptoethanol (BME). A similar approach could be extended to a class A GPCR using GhrelON, a benzylguanine-linked peptide agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), which is involved in food intake and growth. Thus, ExONatide and GhrelON allow SNAP-tag-directed activation of class A and B GPCRs involved in gut hormone signaling in a reversible manner. This tactic, termed reductively cleavable agONist (RECON), may be useful for understanding GLP-1R and GHS-R1a function both in vitro and in vivo, with applicability across GPCRs

Synthesis of fluorosugar reagents for the construction of well-defined fluoroglycoproteins.

2-Deoxy-2-fluoroglycosyl iodides are privileged glycosyl donors for the stereoselective preparation of 1-Nu-β-fluorosugars, which are useful reagents for chemical site-selective protein glycosylation. Ready access to such β-fluorosugars enables the mild and efficient construction of well-defined fluoroglycoproteins.We thank the European Commission (Marie Curie CIG, O.B. and G.J.L.B.), MICINN, Spain (Juan de la Cierva Fellowship, O.B.), MINECO, Spain (CTQ2011-22872BQU) and Generalitat de Catalunya (M.S.) for generous financial support. We also thank Mr. Adrià Cardona-Benages (URV) for technical assis-tance. G.J.L.B. thanks the Royal Society (University Research Fellowship), Fundação para a Ciência a Tecnologia, Portugal (FCT Investigator), and the EPSRC for funding.This is the final version of the article. It first appeared from ACS via http://pubs.acs.org/doi/abs/10.1021/acs.orglett.5b01259

Mucins and Pathogenic Mucin-Like Molecules Are Immunomodulators During Infection and Targets for Diagnostics and Vaccines

Mucins and mucin-like molecules are highly O-glycosylated proteins present on the cell surface of mammals and other organisms. These glycoproteins are highly diverse in the apoprotein and glycan cores and play a central role in many biological processes and diseases. Mucins are the most abundant macromolecules in mucus and are responsible for its biochemical and biophysical properties. Mucin-like molecules cover various protozoan parasites, fungi and viruses. In humans, modifications in mucin glycosylation are associated with tumors in epithelial tissue. These modifications allow the distinction between normal and abnormal cell conditions and represent important targets for vaccine development against some cancers. Mucins and mucin-like molecules derived from pathogens are potential diagnostic markers and targets for therapeutic agents. In this review, we summarize the distribution, structure, role as immunomodulators, and the correlation of human mucins with diseases and perform a comparative analysis of mucins with mucin-like molecules present in human pathogens. Furthermore, we review the methods to produce pathogenic and human mucins using chemical synthesis and expression systems. Finally, we present applications of mucin-like molecules in diagnosis and prevention of relevant human diseases